A global leader in the development of new medications for patients with serious mental illness discussed recently what needs to be done to make a real difference in their treatment.
Oxford University Professor Husseini Manji and his colleagues were the recent recipients of the 2023 Rhoda and Bernard Sarnat International Prize in Mental Health for the development of the antidepressant esketamine for those patients suffering with treatment resistant depression.
Professor Manji who works closely with Oxford Health NHS Foundation Trust and the Oxford Health Biomedical Research Centre (OH BRC) as Co-chair of the NIHR Mental Health Translational Research Collaboration (MH TRC) Mental Health Mission spoke at The American College of Neuropsychopharmacology 2023 Annual Meeting this weekend.
Professor Manji discussed the need for investment into the development of medication for serious mental illness during his President’s Plenary session.
The annual meeting, which took place in Tampa Florida, is one of the world’s leading forums for the exchange of cutting-edge scientific information about the brain, behaviour, and psychotropic drugs. This year the event offered an opportunity for those attending to learn about the most recent and often unpublished advances in psychopharmacology.
Professor Manji’s goal, along with his team is to discover and develop new treatments for serious mental illnesses including psychiatric and pain-related diseases where effective treatments are few and far between.
You can read more about Professor Manjis contribution during the annual meeting on the Psychiatric Times website.
